Eli Lilly Adds Warning Labels To Zyprexa

Law360, New York (October 9, 2007, 12:00 AM EDT) -- Drug maker Eli Lilly and Co. has decided to put stronger product labels on its blockbuster antipsychotic treatment Zyprexa, adding new warnings about the potential for weight gain and elevated blood sugar or cholesterol levels.

Zyprexa, the brand name version of olanzapine, is an atypical anti-psychotic prescription medication used to treat symptoms of various psychiatric conditions, including schizophrenia and bipolar disorder.

Lilly said the decision reflected both new analysis of clinical trial data and ongoing discussions with the U.S. Food and Drug Administration. The company also...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.